JFrog stock rises as Cantor Fitzgerald maintains Overweight rating after strong Q2
Investing.com - JMP Securities has reiterated its Market Outperform rating and $15.00 price target on Solid Biosciences (NASDAQ:SLDB) stock, citing progress in the company’s Duchenne muscular dystrophy (DMD) program. The $520 million market cap company has shown strong momentum, with shares surging over 65% in the past six months. According to InvestingPro data, analyst targets range from $10 to $20, suggesting significant potential upside.
The firm noted that Solid Biosciences has dosed 15 DMD patients ahead of schedule and plans to meet with the FDA in the fourth quarter of 2025 to discuss regulatory pathways for its SGT-003 therapy.
JMP expressed encouragement over the rapid enrollment progress in the DMD program despite recent market volatility caused by competitor Sarepta Therapeutics, suggesting continued demand for genetic medicines in DMD and pointing to differentiation in Solid’s approach.
The research firm believes Solid Biosciences maintains "best-in-class microdystrophin levels and distribution driven by its capsid technology" and expects an update from the company around year-end, along with regulatory clarity.
JMP also highlighted Solid’s pipeline expansion, with Phase 1 trials for Friedreich’s ataxia (SGT-212) and catecholaminergic polymorphic ventricular tachycardia (SGT-501) set to begin enrollment in the fourth quarter of 2025, noting these developments are "currently not captured by investors."
In other recent news, Solid Biosciences has received Fast Track designation from the U.S. Food and Drug Administration for its gene therapy candidate SGT-501, aimed at treating catecholaminergic polymorphic ventricular tachycardia (CPVT). This designation allows for more frequent interactions with the FDA and potential eligibility for priority review. Additionally, Solid Biosciences’ stock ratings have been reiterated by several analyst firms. Cantor Fitzgerald maintained an Overweight rating with a $16.00 price target, highlighting safety concerns with competitor Sarepta Therapeutics’ treatment. JMP Securities reiterated its Market Outperform rating, citing the larger AAV-naive Duchenne muscular dystrophy patient population as a positive factor. Meanwhile, Citi upheld a Buy rating with a $14.00 price target, noting the FDA’s investigation into Sarepta’s Elevidys treatment. These developments come amid ongoing discussions about the Duchenne muscular dystrophy and gene therapy landscape.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.